Life Science and Biotech CEO stories (Tim Dougherty)

It’s shocking that 106,000 people die every year from adverse drug reactions. Moreover, 350,000 people are hospitalized every year, 1.3 million people go to the ER, and it is the fourth leading cause of death in the United States. Adverse drug reactions are a behemoth problem, costing the economy almost half trillion dollars.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Welcome to the podcast writeup for the Life Science and Biotech CEO stories podcast.

In this episode we chat with Dr. Jayne Morgan who is the Director of the Covid Task Force at the Piedmont Healthcare Corporation in Atlanta, GA, a cardiologist, and a Covid vaccine expert. Dr. Morgan manages communications in a public health crisis for the entire state of Georgia – and a politically-charged one at that! We discuss Dr. Morgan’s efforts to educate the public about the Covid vaccine as an outstanding example of health equity in today’s age.

What is health equity?

Health equity is defined as giving everyone the same chance to be healthy, regardless of race, social status, gender, or any other circumstances within that person’s state of being.

Here's where inspirational physicians and Covid vaccine experts like Dr. Morgan play a key role in health equity. With modern technology and artificial intelligence, there are large parts of medicine that are moving directly to the consumer, and are given to the consumer’s hands. You can monitor your own heart rate, for example, using a wearable device. You can participate in clinical trials about diseases that affect people like yourself. For example, Dr. Morgan’s passion is increasing minority recruitment into clinical trials.

There is a huge opportunity for members of the community – whether they be physicians, medical experts, community leaders, and community members themselves – to exert their influence over others and encourage them to participate in these health equity initiatives for the betterment of not just their own health but that of others.

She started filming herself discussing the Covid vaccine from the stairs of her house, and had no idea the legs that it would take on – at first, she thought it was just going to be a few episodes. It turned into an entire series. Her goal was to combat the misinformation and the intentional disinformation about the Covid campaigns. In many of her videos she addresses questions posed on social media about the Covid vaccine.

Her biggest challenge was in the fourth surge (the Delta variant) when disinformation was driving a lot of chaos in the minds of the public. She took on this nonsense hocus pocus (mostly from social media) in her Stairwell Chronicles. She took it head on and encouraged other doctors and Covid experts to address it as well.

The reason Dr. Morgan’s efforts are a great example of health equity in action is because of how they were done. Her educational snippets about the vaccine are filmed from the stairs of her home, and her communication style is clear, relatable, and to the point. She distributed them over social media and made it easy for people to access them. Not the typical clinical-sounding video of a doctor in a lab coat preaching about medical tips.

Those looking to improve health equity in their community could take a page from Dr. Morgan’s book. Knowledge is empowering and it’s even more easily received if you can talk to people on their level and focus on making complicated subjects comfortable and understandable.

We hope that you’ll listen to the podcast with inspiring doctor and Covid expert Dr. Jayne Morgan.

Music is Positive Fuse by French Fuse

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Recently on the Biotech and Life Science CEO’s podcast, we’ve been talking about the speed at which change is occurring in the life sciences. And nowhere is that clearer than in the field of mRNA. By now everyone must know that the COVID vaccines were created literally days after the genome of the virus had been sequenced. But I don’t think we’ve still processed what that really means.

Our guest today is Dr. Pooja Tiwari, the founder of Arnav Biotech, dedicated to the design and manufacture of both custom and cataloged mRNA for use in therapeutic vaccine, diagnostic, and even agricultural applications.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we are joined by Charles DeCoster, CEO, and Tony Watson, COO, of Xenocor, a company that is revolutionizing laparoscopic surgery with a new scope they call Saberscope. This device was designed to be less expensive, more effective at providing the surgeon with available light, and safer for the patient.

Laparoscopic surgery was invented in the 1980’s and the technology platform is now 30 years old. It has not changed dramatically since then. The single use model eliminates a lot of the frustrations. You open up the package, you plug it in. That’s the whole workflow. A reusable scope’s workflow, from the time it gets opened in the OR to the time it gets back to the OR to be used again, is quite onerous. By making it single use, they are reducing waste and simplifying the process.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today I am really excited to have Charles Gellman, CEO of HiDO Health. HiDO is a company that is focused on using artificial intelligence to help patients manage their medications for chronic disease. Each year, almost 250,000 in America die as a result of medical errors associated with lack of adherence to a prescription schedule, making it the third largest cause of death in the US.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Gaurav Byagathvalli, a Geoge Tech alum and the CEO of Piezo Therapeurtics, a company developing an innovative nucleic acid delivery platform for DNA and mRNA vaccines. Instead of using complicated equipment they use simplified circuits, analogous to what is in a lighter, to product the same impulse. They then use microneedles, which function as electrodes, to conduct those pulses into your skin resulting in highly targeted, localized delivery.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast we interview Dr. Nikhil Shah, the CEO and Co-Founder of Nephrodite, Inc., an early-stage start up medical device company focused on developing an implantable continuous functioning dialysis device.

Disclaimers

The information contained in this website and  podcast are purely informational and not considered investment  recommendations. Tim Dougherty’s participation in Biotech Insights is  separate and apart from his role as an investment advisor  representative. Nothing contained herein may be construed as a  recommendation or endorsement of any of the companies discussed. Tim  Dougherty has no financial affiliation with any of the companies  mentioned in this communication. Tim Dougherty makes no representation  that the information conveyed in this material is accurate and is under  no obligation to update this information as changes occur.

In this episode of the Biotech and Life Sciences CEO podcast, we meet with Berkshire Biomedical CEO John Timberlake to discuss how they are making innovations in personalized medication delivery.   Through their COPA product, which stands for Computerized Oral Prescription Administration, they are coming up with new ways to ensure that liquid medications are delivered at the right time, in the right amount, and only to the authenticated, intended user.  For more episodes of inspirational Biotech and Life Sciences CEOs, visit our podcast site:  https://www.biotechinsights.net/

Tim Dougherty 

tim@biotechinsights.net  

About John Timberlake John Timberlake has served as Berkshire Biomedical’s Chief Executive Officer, President, and a member of our Board of Directors since April 2021. Mr. Timberlake has more than 30 years of life sciences experience in bringing pharmaceuticals, medical devices, and drug-device combination products to market.  Most recently, Mr. Timberlake was chief executive officer, president, and a member of the board of directors for Valeritas Holdings, Inc. During his fourteen‐year tenure at Valeritas, he advanced from General Manager to Chief Commercial Officer, and ultimately to Chief Executive Officer and Board Member in February 2016. Mr. Timberlake commercialized their lead product, V‐Go®; took the company public; and executed the sale of the company to Zealand Pharma in April 2020.  For the fifteen years prior to Valeritas, he held varying leadership roles across corporate finance, and the commercial organization at Sanofi and its predecessor companies. As Director of New Product Commercialization for Metabolism and subsequently Vice President of Diabetes Portfolio Brand Management for Sanofi, he was instrumental in creating the multi‐billion‐dollar diabetes franchise of insulins and oral antidiabetic prescription products, including Lantus®, the company's block-buster basal insulin.  Prior to that, he was an auditor with Deloitte and left the firm after five years as an Audit Manager. Mr. Timberlake was both a certified management accountant and a certified public accountant. He earned his Bachelor of Science in Accounting at Northwest Missouri State University, a Master of Science in Management at the Krannert School of Management, Purdue University, and a Master of Business Administration at the ESC Rouen in Rouen, France (now the NEOMA Business School).  

Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.  Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

We’re going to talk with Peter Pitts, President of Center for Medicine in the Public Interest, about the IRA, which is impacting every company in biotech. The Inflation Reduction Act, or IRA, authorizes the price negotiation for a group of medicines selected by the government and, interestingly, allows no public pronouncements after the fact, by the companies.

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures.

Enjoy the show!

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we’re excited to have Subh Roy who will share his insights about how to get funding for your biotech.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this episode we talk about gene algorithms with Raymond Peterson of DNA Analytics.

The information contained in this website and podcast are purely  informational and not considered investment recommendations. Tim  Dougherty’s participation in Biotech Insights is separate and apart from  his role as an investment advisor representative. Nothing contained  herein may be construed as a recommendation or endorsement of any of the  companies discussed. Tim Dougherty has no financial affiliation with  any of the companies mentioned in this communication. Tim Dougherty  makes no representation that the information conveyed in this material  is accurate and is under no obligation to update this information as  changes occur.

This is the story of Tan Rasab, the co-founder of SiGENEX, whose mission is to enable genetic testing at point of need at a price point reasonable to the common man. Read this inspirational interview to hear about the exciting innovations being made in genetic sequencing and what it may mean for hospitals, clinicians, patients, and society!

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast, we are joined by historian Dr. Nicolas Hoffmann who recounts a slew of quirky Civil War medicine stories that will have you rolling in laughter.

Let’s go!

Over the last few months of this podcast, we’ve had the opportunity to learn about tiny pill-sized endoscopes that can be swallowed and controlled on their path through the digestive tract by the healthcare provider.

We’ve heard about the prospects for a universal flu vaccine whose chemistry would be consistent from one year to the next whose efficacy could be better than 90%.

A smaller, less expensive tool for targeted genetic sequencing.

And many other amazing innovations.

In other words, things are happening really fast.

But today, our thought is a little bit different. We’re going to try to juxtapose history with what is currently happening in an effort to demonstrate exactly what those changes are and how fast those changes are going to be.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases.

What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

There are 1.4 million meniscus procedures performed in the US and Europe every single year. Most of those are meniscetomy which is when the meniscus is removed. The problem is that once it is gone, so is the cushioning that protects the knee joint and cartilage, accelerating arthritis. A quarter of people continue to have pain after a few years. Millions of people have this procedure and it’s not the best answer.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Dr. Amy Baxter, the CEO of Pain Care Labs, a company dedicated to using mechanical platforms such as vibrating devices to alleviate fear and pain associated with needles as well as reducing muscular skeletal pain in adults.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast we welcome Harry Glorikian, an author, innovator, and podcast host in life sciences. In Harry’s book, The Future You, he alludes to artificial intelligence, or AI, as having the ability to unlock the language of life. In this podcast we discuss the impact that technology is having on the economics of healthcare, what the future hospital and doctor’s office of the future are likely to look like, and more!

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Raised by hang-gliding hippies traveling through Mexico and South America, Torrey Smith later became a successful aerospace engineer. But the idea of sending in the nanobots to fix biological ailments inside human beings was a frustrating one for Torrey Smith. As he had only seen the idea conceptualized in  science fiction, he wondered why nobody has managed to achieve it in real life. And he just may become the first one to do it! In this interview we cover the career path of CEO Torrey Smith, the co-founder of medical robotics company Endiatx, maker of the PillBot; his mission, his unconventional spirit, and his pursuit of progressive thinking.

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast, we are pleased to have Mike Walsh, CEO of Patient Advocacy Strategies as our guest. Patient advocacy may seem like a “nice to have” or an afterthought. In this podcast you’ll learn why the opposite is true – that it’s important to glean input from patient groups early on in the lifecycle and throughout the course of developing solutions for patients.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this episode, filed at Science Square in Atlanta, we speak with David Francis and Mighten Yip of Palate Therapeutics, whose mission is to alter people’s food preferences away from sugary foods using therapeutic mouthwash.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Tune in for this insightful podcast with David Weinstock, the Vice President of Discovery Oncology at Merck, to find out what pharma investors really think when they are interviewing startups looking for funding.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show!

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

There are currently the following bottlenecks to the manufacturing of biologics, or medications such as gene therapies, vaccines, and etc. that are derived from organic sources such as plants or animals.

The obstacles to large scale biologic dissemination are:

1. Delivering the biologic to the target

2. Manufacturing, producing it at scale

3. Selecting patients for clinical trials in a way that enhances the efficacy of the trial

These challenges have, up until now, made biologics more expensive to administer and that higher price tag can make access limited to the population at large. Significant improvement will come when those bottlenecks release.

Are we on the verge of a breakthrough?

We are pleased to interview Dr. Alexander Koglin, co-founder and CSO of Nature’s Toolbox, in this month’s show who will discuss the progress that is being made in biomanufacturing and what it may mean for society.

The information contained in this website and podcast are purely informational and not considered

investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart

from his role as an investment advisor representative. Nothing contained herein may be construed as a

recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial

affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no

representation that the information conveyed in this material is accurate and is under no obligation to

update this information as changes occur.

This episode we’re doing something different. We’re visiting some of the most compelling stories and CEOs of our earlier editions, to update their journeys. I wanted to do this for two reasons.

·       The people in this industry are some of the grittiest, most determined, and most philanthropic, in terms of their commitment to their science and patients, people that I have ever known.

·       By following these individual journeys I hope somehow to demonstrate the incredibly fast pace of innovations taking place.

Our guests are:

·       Abdulkader Rahmo, PhD

·       Torrey Smith

·       Dr. Nikhil Shah

·       Tan Rasab

·       Jacob Glanville

Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Dr. Dennis Liotta is very humble but don’t let that fool you – underneath the poised demeanor he’s a impassioned drug discovery giant who has made a significant contribution to improving the disease state of the world’s poor.

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast we interview William Miller, MD, an evolutionary biologist, who is developing Cognition-Based Evolution as a novel peer-accepted alternative to conventional evolutionary theory.

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we are honored to have Dr. Josep Bassaganya-Riera, President and CEO of NImmune Biopharma, to talk about how his company is leveraging computational modeling and bioinformatics to develop new therapeutics.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this episode we interview Abdulkader Rahmo, PhD, (nicknamed “AB”) co-founder, President and Chief Scientific Officer of SMSbiotech about the advances in stem cell research that he and his company have made. Lots of inspiration here!

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we are going to discuss advancements in improving the efficiency of those clinical trials. Our guest is Ian Strug who is the co-founder and Chief Revenue Officer at Virgo Surgical Video Solutions. Virgo provides cloud video capture, management, and artificial intelligence analysis for endoscopic medicine.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative.

Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is another Atlanta luminary, Dr. Marvin Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections.

It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics.

How can this trend be stopped?  

Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

With over 1.5 million people suffering traumatic brain injuries a year, 80,000 stroke victims, and millions of concussions, the impact that brain impairment has on society is not to be ignored. We spoke with William Korinek of Astrocyte Pharmaceuticals, who is developing neuroprotein therapies for these conditions.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Dr. Ivan Liachko, the CEO of Seattle-based Phase Genomics, a company whose core technology is ultra-long range genome sequencing. He’s also the founder of Genome Startup Day, dedicated to helping new biotech entrepreneurs transition from academic settings into industry and entrepreneurship.

Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we have four very special guests, some friends of mine, who are going to share with us the story behind all the momentum driving life sciences in Atlanta.

· Eddie Lai represents the MetroAtlanta Chamber of Commerce

· Courtney Law represents a group called Biolocity, which bridges Emory and Georgia Tech

· Ryan Lawler is from Biosparks Labs, funded by Georgia Technology Ventures, supporting the life science community in Atlanta

· Suna Lumeh is from a venture capital firm called Portal Innovations

This was a great group so I hope you’ll listen to the show! Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

In this podcast we’re pleased to welcome Jacob Glanville, the CEO of Centivax. He is working on a single, broad-spectrum vaccine, initially for the flu.